The consistency of clinical and biomarker effects of these four anti-amyloid agents provides robust evidence for the role of Aβ oligomers as upstream initiator of AD pathogenesis that triggers tau pathology, neurodegeneration, and resultant cognitive impairment (Table 1). Here, MAPT is linked to Cognitive impairment.